论文部分内容阅读
目的比较中晚期鼻咽癌新辅助性化疗加放疗与单纯放疗的疗效。方法 119例中晚期鼻咽癌患者,随机分为新辅助性化疗+放疗组(46例,行新辅助性化疗加放疗)和放疗组(73例,行单纯放疗)。观察比较两组疗效。结果放疗组、新辅助性化疗+放疗组完全缓解率分别为95.89%、100.00%,比较差异无统计学意义(P>0.05)。放疗组1年内复发转移5例(6.85%),新辅助性化疗+放疗组2例(4.35%);放疗组2年内复发转移19例(26.03%),新辅助性化疗+放疗组7例(15.22%);放疗组3年内复发转移24例(32.88%),新辅助性化疗+放疗组7例(15.22%)。两组1、2年复发转移率比较差异无统计学意义(P>0.05);放疗组3年复发转移率明显高于新辅助性化疗+放疗组,差异有统计学意义(P<0.05)。放疗组1年无病生存率为93.15%、2年无病生存率为73.97%、3年无病生存率为67.12%;新辅助性化疗+放疗组分别为95.65%、84.78%、84.78%。新辅助性化疗+放疗组3年无病生存率高于放疗组,差异有统计学意义(P<0.05)。结论中晚期鼻咽癌患者行新辅助性化疗加放疗的效果优于单纯放疗。
Objective To compare the efficacy of neoadjuvant chemotherapy plus radiotherapy and radiotherapy in moderate and advanced nasopharyngeal carcinoma. Methods One hundred and ninety - nine patients with advanced nasopharyngeal carcinoma were randomly divided into neoadjuvant chemotherapy + radiotherapy group (n = 46, neoadjuvant chemotherapy plus radiotherapy) and radiotherapy group (n = 73, treated with radiotherapy alone). Observation and comparison of two groups efficacy. Results The complete remission rates of radiotherapy group and neoadjuvant chemotherapy + radiotherapy group were 95.89% and 100.00%, respectively, with no significant difference (P> 0.05). In the radiotherapy group, 5 cases (6.85%) relapsed and metastasized in 1 year, 2 cases (4.35%) in neoadjuvant chemotherapy plus radiotherapy group, 19 cases (26.03%) in radiotherapy group within 2 years, 7 cases in neoadjuvant chemotherapy + radiotherapy group 15.22%). In the radiotherapy group, 24 cases (32.88%) relapsed within 3 years and 7 cases (15.22%) in the neoadjuvant chemotherapy plus radiotherapy group. There was no significant difference in the recurrence and metastasis rates between the two groups in one and two years (P> 0.05). The recurrence and metastasis rates in the three-year radiotherapy group were significantly higher than those in the neoadjuvant chemotherapy + radiotherapy group (P <0.05). The 1-year disease-free survival rate was 93.15% in radiotherapy group. The 2-year disease-free survival rate was 73.97%. The 3-year disease-free survival rate was 67.12%. The neoadjuvant chemotherapy + radiotherapy group was 95.65%, 84.78% and 84.78% respectively. Neoadjuvant chemotherapy + radiotherapy group 3-year disease-free survival rate was higher than radiotherapy group, the difference was statistically significant (P <0.05). Conclusions Neoadjuvant chemotherapy plus radiotherapy is superior to radiotherapy alone in patients with advanced nasopharyngeal carcinoma.